Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220551 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants
A Phase 1 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT07220551: Completed Phase 1 study, sponsored by UCB Biopharma SRL.
NCT07220551 is a Phase 1 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220551, a Phase 1 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the relative bioavailability of UCB0022 Formulation 2 (Test) versus Formulation 1 (Reference) in healthy participants following single oral administration.
Primary Outcome
AUC: Area under the plasma concentration-time curve.
Interventions
- DRUG UCB0022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 1 |
What the finished NCT07220551 record still lists
NCT07220551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which UCB0022 is the first listed.
NCT07220551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07220551 about?
NCT07220551 is a clinical study titled "A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants". The purpose of this study is to estimate the relative bioavailability of UCB0022 Formulation 2 (Test) versus Formulation 1 (Reference) in healthy participants following single oral administration.
What is the current status of trial NCT07220551?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2025-10-23. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT07220551?
The interventions under investigation include: UCB0022 (DRUG).
Who is sponsoring clinical trial NCT07220551?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07220551's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy